Belinostat
Histone Deacetylase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: beleodaq, PXD101
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Belinostat is an onp drug in the Histone Deacetylase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Histone Deacetylase Inhibitors. DrugCentral lists 15 molecular targets, including HDAC2, HDAC1 and HDAC3. Recorded indications include Peripheral T-cell lymphoma.
- Approval status: onp (first approved 2014 by the FDA).
- Drug class: Histone Deacetylase Inhibitor.
- Mechanism of action: Histone Deacetylase Inhibitors.
- Molecular targets: HDAC2, HDAC1, HDAC3 and HDAC6 (15 listed in DrugCentral).
- Indications: Peripheral T-cell lymphoma.
- ATC code: L01XH04 (Histone deacetylase (HDAC) inhibitors).
- Molecular formula: C15H14N2O4S; molecular weight 318.35 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Peripheral T-cell lymphoma
Mechanism & targets
| Mechanism of action (MoA) | Histone Deacetylase Inhibitors |
|---|---|
| Established pharmacologic class | Histone Deacetylase Inhibitor |
Molecular targets (15)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Histone deacetylase 2 | HDAC2 | inhibitor | Ki 9.07 |
| Histone deacetylase 1 | HDAC1 | inhibitor | Ki 9.07 |
| Histone deacetylase 3 | HDAC3 | inhibitor | Ki 8.82 |
| Histone deacetylase 6 | HDAC6 | inhibitor | Ki 8.80 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | PIK3CA | unknown | IC50 8.54 |
| Histone deacetylase 8 | HDAC8 | inhibitor | Ki 7.66 |
| Histone deacetylase 9 | HDAC9 | inhibitor | Ki 7.62 |
| Histone deacetylase 5 | HDAC5 | inhibitor | Ki 7.60 |
| Bromodomain-containing protein 4 | BRD4 | unknown | IC50 7.57 |
| Histone deacetylase 11 | HDAC11 | inhibitor | Ki 7.57 |
| Histone deacetylase 4 | HDAC4 | inhibitor | IC50 7.57 |
| Histone deacetylase 7 | HDAC7 | inhibitor | Ki 7.29 |
| Histone deacetylase 10 | HDAC10 | inhibitor | Ki 7.23 |
| Histone deacetylase | HDAC1 | unknown | IC50 6.67 |
| Aspartyl/asparaginyl beta-hydroxylase | ASPH | unknown | IC50 5.51 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-07-03 | FDA | — | SPECTRUM PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01XH04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Histone deacetylase (HDAC) inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label
- FDA label: UGT1A1 · Actionable PGx
- HCSC label
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Disease progression | 146.5 |
| Neutrophil count decreased | 43.6 |
| Platelet count decreased | 43.4 |
| Anaemia | 42.6 |
Chemical structure
| Molecular formula | C15H14N2O4S |
|---|---|
| Molecular weight | 318.35 g/mol |
| CAS number | 414864-00-9 |
| InChIKey | NCNRHFGMJRPRSK-UHFFFAOYSA-N |
| PubChem CID | 6918638 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Belinostat used for?
DrugCentral lists the following indications for Belinostat: Peripheral T-cell lymphoma.
How does Belinostat work?
Belinostat is classified as Histone Deacetylase Inhibitors; its molecular targets in DrugCentral include HDAC2 (inhibitor), HDAC1 (inhibitor), HDAC3 (inhibitor) and HDAC6 (inhibitor).
When was Belinostat first approved?
Belinostat was first approved by the FDA in 2014.
What drug class does Belinostat belong to?
Belinostat is in the Histone Deacetylase Inhibitor class.
What is the chemical formula of Belinostat?
Belinostat has the molecular formula C15H14N2O4S and a molecular weight of 318.35 g/mol.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4876 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL408513 — compound record and bioactivity
- PubChem CID 6918638 — chemical identifiers
- DrugBank DB05015 — drug record
- FDA UNII F4H96P17NZ — substance identity
- DailyMed: FDA labels for Belinostat — current prescribing information (label search)
- UniProt Q92769 (HDAC2) — target protein
- UniProt Q13547 (HDAC1) — target protein
- UniProt O15379 (HDAC3) — target protein
- UniProt Q9UBN7 (HDAC6) — target protein
- UniProt P42336 (PIK3CA) — target protein
- UniProt Q9BY41 (HDAC8) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.